{'fraction_non_alphanumeric': 0.024024024024024024, 'fraction_numerical': 0.0, 'mean_word_length': 5.947916666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis

Tumour necrosis factor (TNF)‐α inhibitors represent potent new therapies for severe forms of psoriasis, psoriatic arthritis, and several other immune‐mediated disorders. Paradoxical worsening or de novo development of psoriasis has been documented with their use. Palmoplantar pustulosis has been one of the commoner presentations of this unusual side effect. Subcorneal pustular dermatosis (SPD) has some similarity to pustular psoriasis, particularly the acral form of SPD. Thus far there have been no biopsy‐proven cases of SPD associated with TNF‐α inhibitor use.